Syros Pharmaceuticals, Inc.

Research Syros Pharmaceuticals, Inc. (0LC7) with Bullrun company financials, valuation charts, model signals, and historical stock context.

Key Metrics

• Ticker0LC7
• ExchangeLSE
• CountryUnited States
• CurrencyUSD

About Syros Pharmaceuticals, Inc.

Syros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatment for hematologic malignancies. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia;

Frequently asked questions

What does Syros Pharmaceuticals, Inc. do?

Syros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatment for hematologic malignancies.